OrbiMed, a leading global healthcare investment firm, has raised $1.86 billion for the OrbiMed Royalty and Credit Opportunities Fund V.
This fund will provide tailored investment solutions, focusing on non-dilutive credit and royalty-based financing for growth-oriented healthcare companies in sectors like biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services.
Investors include medical institutions, university endowments, foundations, pension funds, sovereign wealth funds, and family offices.
KEY QUOTES:
“Equity markets have been challenging in recent years for biotech and life sciences companies. Our flexible, non-dilutive capital solutions can help our portfolio companies to grow and thrive despite these volatile market conditions. The OrbiMed platform is uniquely positioned to fund healthcare innovation and growth on a global basis.”
OrbiMed General Partner Matthew Rizzo
“Over 90% of Fund V’s committed capital is from existing, long-standing firm relationships. We are grateful for this support, and will endeavor to deliver exceptional results to our partners.”
OrbiMed Managing Partner Carter Neild
